SCHEMBL6777095

SCHEMBL6777095

C#CCC(NC(=O)CNC(=O)c1cccc(N/C(=N/C#N)NC)c1)C(=O)OCC

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 1/20 0.43
ITGA5 P08648 1/20 0.43
ALDH1A1 P00352 2/20 0.40
GPR139 Q6DWJ6 5/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NR1H4 Q96RI1 1/20 0.35
POLB P06746 2/20 0.35
TP53 P04637 1/20 0.35
PKM P14618 1/20 0.35
RAB9A P51151 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.34
GMPS P49915 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6777344 0.90 ITGB1 (0.51) ITGB1ITGA5GPR139KMT2AMEN1
SCHEMBL6777100 0.85 ITGB3 (0.43) ITGB1ITGA5ALDH1A1GPR139KMT2A
SCHEMBL7342951 0.84 ALDH1A1 (0.45) ALDH1A1GPR139KMT2AMEN1SMN1; SMN2
SCHEMBL6778103 0.82 ALDH1A1 (0.43) ALDH1A1GPR139KMT2AMEN1TSHR
SCHEMBL6784055 0.82 ALDH1A1 (0.44) ITGB1ITGA5ALDH1A1GPR139KMT2A
SCHEMBL6774133 0.81 TP53 (0.45) ITGB1ITGA5ALDH1A1GPR139KMT2A
SCHEMBL6777350 0.80 ITGB1 (0.45) ITGB1ITGA5GPR139KMT2AMEN1
SCHEMBL6776731 0.79 NAMPT (0.49) ALDH1A1GPR139KMT2AMEN1MAPK1
SCHEMBL7350678 0.79 ITGB1 (0.53) ITGB1ITGA5GPR139LMNA
SCHEMBL6777103 0.77 ITGB1 (0.38) ITGB1ITGA5ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed